Top

Published in:

01-12-2015 | Breast Oncology

Pleomorphic Lobular Carcinoma In Situ: Radiologic–Pathologic Features and Clinical Management

Authors: Meghan R. Flanagan, MD, Mara H. Rendi, MD, PhD, Kristine E. Calhoun, MD, Benjamin O. Anderson, MD, Sara H. Javid, MD

Published in: Annals of Surgical Oncology | Issue 13/2015

Abstract

Background

Pleomorphic lobular carcinoma in situ (PLCIS) is an unusual variant of LCIS for which optimal management remains unclear.

Methods

We conducted a 15-year (2000–2014) retrospective chart review of the radiologic, pathologic, clinical management, and recurrence rates of patients with PLCIS on diagnostic biopsy. Fifty-one patients were found to have PLCIS either alone or with concomitant breast cancer. Of these, 23 were found to have pure PLCIS on diagnostic biopsy. Rates of upstaging after local excision, positive or close margins, mastectomy, and recurrence associated with pure pleomorphic lobular carcinoma in situ were examined.

Results

Of the 21 patients who underwent surgical excision following diagnostic biopsy, 33.3 % (7/21) were found to have invasive carcinoma, and 19 % (4/23) were found to have ductal carcinoma in situ. Extensive or multifocal PLCIS was present in 47.6 % (10/21) of patients, corresponding to at least one PLCIS-positive or close margin in 71.4 % (15/21). In total, there were 11 local re-excisions in nine patients, and 12 mastectomies. No ipsilateral breast cancer events have occurred, including in those with positive or close surgical margins (mean follow-up 4.1 years).

Conclusions

Patients with isolated PLCIS on diagnostic biopsy are at high risk of upgrading to invasive cancer or ductal carcinoma in situ at diagnostic excision. PLCIS often is extensive, with high rates of positive or close surgical resection margins. If negative PLCIS margins are pursued, rates of successful breast conservation are low. In light of this and low recurrence rates, caution should be exercised in aggressively treating PLCIS with excision to clear margins.

Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.CrossRefPubMed

Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.CrossRefPubMed

Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–112. doi:10.1002/cncr.21864.CrossRefPubMed

Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.CrossRefPubMed

Nagi CS, O’Donnell JE, Tismenetsky M, Bleiweiss IJ, Jaffer SM. Lobular neoplasia on core needle biopsy does not require excision. Cancer. 2008;112(10):2152–8. doi:10.1002/cncr.23415.CrossRefPubMed

Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med. 2010;134(7):1024–8. doi:10.1043/2009-0300-OA.1.PubMed

Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8. doi:10.1245/s10434-012-2534-9.CrossRefPubMed

Theriault R, Carlson R. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network; 2013.

Nelson HD, Smith MEB, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(8):604–14. doi:10.7326/0003-4819-158-8-201304160-00005.CrossRefPubMed

10.

Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88. doi:10.1093/jnci/90.18.1371.CrossRefPubMed

11.

Rosen PP, Hoda SA. Breast pathology. Lippincott Williams & Wilkins, Philadelphia; 2010.

12.

Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;5(3):546–53. doi:10.5306/wjco.v5.i3.546.PubMedCentralCrossRefPubMed

13.

Murray L, Reintgen M, Akman K, et al. Pleomorphic lobular carcinoma in situ: treatment options for a new pathologic entity. Clin Breast Cancer. 2012;12(1):76–9. doi:10.1016/j.clbc.2011.08.007.CrossRefPubMed

14.

Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol. 2008;32(11):1721–6. doi:10.1097/PAS.0b013e31817dc3a6.CrossRefPubMed

15.

Carder PJ, Shaaban AM. Pleomorphic lobular carcinoma in situ. Diagn Histopathol. 2012;18:119–123.CrossRef

16.

Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situof the breast: clinicopathological review of 47 cases. Histopathology. 2014;64(7):981–93. doi:10.1111/his.12353.PubMedCentralCrossRefPubMed

17.

Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW. Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013;19(1):116–8. doi:10.1111/tbj.12062.CrossRefPubMed

18.

19.

Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–41. doi:10.1056/NEJMra031301.CrossRefPubMed

20.

Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135(6):737–43. doi:10.1043/2010-0204-OA.1.PubMed

21.

Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH. Lobular in situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012;19(3):914–21. doi:10.1245/s10434-011-2034-3.CrossRefPubMed

22.

Esserman LE, Lamea L, Tanev S. Should the extent of lobular neoplasia on core biopsy influence the decision for excision? Breast J. 2007. doi:10.1111/j.1524-4741.2006.00363.x.

23.

Hussain M, Cunnick GH. Management of lobular carcinoma in situ and atypical lobular hyperplasia of the breast–a review. Eur J Surg Oncol. 2011;37(4):279–89. doi:10.1016/j.ejso.2011.01.009.CrossRefPubMed

24.

25.

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 4th edn. Lyon: International Agency on Cancer Research; 2012:78–80.

26.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi:10.1016/j.jbi.2008.08.010.PubMedCentralCrossRefPubMed

Title: Pleomorphic Lobular Carcinoma In Situ: Radiologic–Pathologic Features and Clinical Management
Authors: Meghan R. Flanagan, MD
Mara H. Rendi, MD, PhD
Kristine E. Calhoun, MD
Benjamin O. Anderson, MD
Sara H. Javid, MD
Publication date: 01-12-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 13/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4552-x

At a glance: The STEP trials

Springer Medicine

Pleomorphic Lobular Carcinoma In Situ: Radiologic–Pathologic Features and Clinical Management

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2015

The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer?

Nodular Regenerative Hyperplasia in Patients Undergoing Liver Resection for Colorectal Metastases After Chemotherapy: Risk Factors, Preoperative Assessment and Clinical Impact

Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes

Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?

Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer

Anaplastic Thyroid Cancer: Large Database, Cautious Interpretations